Aurobindo Pharma is currently trading at Rs. 611.75, up by 11.05 points or 1.84% from its previous closing of Rs. 600.70 on the BSE.
The scrip opened at Rs. 608.80 and has touched a high and low of Rs. 611.90 and Rs. 603.20 respectively. So far 24494 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 537.00 on 05-Aug-2019.
Last one week high and low of the scrip stood at Rs. 611.90 and Rs. 584.30 respectively. The current market cap of the company is Rs. 35197.33 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.23% and 12.90% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare S.V, Netherlands, has entered into an agreement on August 29, 2019 with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.